Methods of treating nerve-related vision disorders by an insulinomimetic agent

• US 8,093,212 B2
• Filed: 10/27/2010
• Issued: 01/10/2012
• Est. Priority Date: 02/28/2002
• Status: Expired due to Fees

• Current Assignee: Penn State Research Foundation
• Original Assignee: Penn State Research Foundation
• Inventors: Gardner, Thomas W., Reiter, Chad E.
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US12/913,327
• Publication Number:
  US 20110065761A1
• Time in Patent Office: 440 Days
• Field of Search: None
• US Class Current: 514/6.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

This invention provides reagents and methods for delivering insulin, insulinomimetic agents, and the like to a vertebrate eye via subconjunctival routes, sub-Tenon'"'"'s routes, or intravitreal routes for treatment of nerve-related vision disorders such as diabetic retinopathy, and formulations useful in the practice of the disclosed methods.

Claims

1. A method of treating a nerve-related vision disorder in a subject in need thereof comprising the step of administering a therapeutically effective amount of a formulation of an insulinomimetic agent to an eye affected by the nerve-related vision disorder via a periocular route, wherein the therapeutically effective amount is effective to achieve a local therapeutic effect without a substantial systemic effect.

2. The method of claim 1 wherein the route is subconjunctival, sub-Tenon'"'"'s or intravitreal.

3. The method of claim 1, wherein the formulation of an insulinomimetic agent further comprises an augmenting drug.

4. The method of claim 3, wherein the augmenting drug is a thiazolidinedione.

5. The method of claim 1, wherein the formulation of the insulinomimetic agent is administered via a solution, a polymeric base, or a pump.

6. The method of claim 1, wherein the formulation of the insulinomimetic agent is administered to the eye by a device implanted therein, wherein the device releases the insulinomimetic agent at a prescribed rate.

7. The method of claim 1, wherein the insulinomimetic agent is administered under the eye'"'"'s surface membrane.

8. The method of claim 1, wherein the formulation of the insulinomimetic agent is administered to both eyes of an individual.

9. The method of claim 1, wherein the formulation of the insulinomimetic agent is administered to one or both eyes of an animal using one or more implanted devices.

10. The method of claim 1, wherein the nerve-related vision disorder is diabetic retinopathy.

11. The method of claim 1 wherein the nerve-related vision disorder is a retinal disorder.

12. The method of claim 11 wherein the retinal disorder is retinal detachment, retinitis pigmentosa, central retinal artery occlusion, central retinal vein occlusion, ischemic optic neuropathy, high tension glaucoma, low tension glaucoma, or cataract.

13. The method of claim 1 where the periocular route is a non-topical periocular route.

14. The method of claim 1 wherein the insulinomimetic agent is a PPAR-gamma activator.